
Mednition is an industry-leading artificial intelligence company that enhances patient, staff, and hospital outcomes through its KATE AI platform, which provides real-time clinical guidance and risk detection in Emergency Departments. The company focuses on a nurse-first approach, integrating seamlessly into existing workflows to improve the identification of critically ill patients without requiring additional work from healthcare staff. With FDA Breakthrough Device Designation for KATE Sepsis, Mednition is positioned as a transformative force in emergency nursing, aiming to save over 1 million patients annually by optimizing outcomes for high-risk conditions using real data and AI technology.

Mednition is an industry-leading artificial intelligence company that enhances patient, staff, and hospital outcomes through its KATE AI platform, which provides real-time clinical guidance and risk detection in Emergency Departments. The company focuses on a nurse-first approach, integrating seamlessly into existing workflows to improve the identification of critically ill patients without requiring additional work from healthcare staff. With FDA Breakthrough Device Designation for KATE Sepsis, Mednition is positioned as a transformative force in emergency nursing, aiming to save over 1 million patients annually by optimizing outcomes for high-risk conditions using real data and AI technology.
Product: KATE AI — EHR-integrated, nurse-centered real-time clinical decision support for EDs
Clinical/Regulatory: KATE Sepsis received FDA Breakthrough Device Designation
Founded / HQ: Founded 2014; Burlingame / San Mateo, California
Funding: $10M Series A (Sept 2019) led by Concord Health Partners
Early detection and triage of high-risk conditions (including sepsis) in emergency departments.
2014
Healthtech / Clinical AI
$10,000,000
“Concord Health Partners led Series A; participation from Wildcat Capital Management and other private healthcare investors”